PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31587305-3	2020	Other studies have shown that knockdown of RB1 and TP53 increases the expression of neuroendocrine markers, decreases the sensitivity to enzalutamide, and increases the expression of SOX2.	enzalutamide	137-149	tumor protein p53	Homo sapiens	51-55	
34728570-6	2022	Enzalutamide induced the expression of DNMT3A and DNMT3B in prostate cancer cells with a potential role of p53 and pRB in this process.	enzalutamide	0-12	tumor protein p53	Homo sapiens	107-110	
35385726-4	2022	AR blockade with enzalutamide induces (1) transcriptional silencing of TP53 and hence dedifferentiation to a hybrid epithelial and mesenchymal and stem-like state and (2) inhibition of BMP signaling, which promotes resistance to AR inhibition.	enzalutamide	17-29	tumor protein p53	Homo sapiens	71-75	
28228262-4	2017	Combination treatment with the AR signaling inhibitor enzalutamide (ENZ) and the Chk1/2 inhibitor AZD7762 demonstrates synergy with regard to inhibition of AR-CDC6-ATR-Chk1 signaling, ATM phosphorylation induction, and apoptosis in VCaP (mutant p53) and LNCaP-C4-2b (wild-type p53) cells.	enzalutamide	54-66	tumor protein p53	Homo sapiens	245-248	
28228262-4	2017	Combination treatment with the AR signaling inhibitor enzalutamide (ENZ) and the Chk1/2 inhibitor AZD7762 demonstrates synergy with regard to inhibition of AR-CDC6-ATR-Chk1 signaling, ATM phosphorylation induction, and apoptosis in VCaP (mutant p53) and LNCaP-C4-2b (wild-type p53) cells.	enzalutamide	54-66	tumor protein p53	Homo sapiens	277-280	
33771885-8	2021	Implications: We identified common and reproducible genomic alterations in CTCs from AR-V7 negative mCRPC men associated with poor outcomes during enzalutamide/abiraterone treatment, including CNAs in genes linked to lineage plasticity and epigenetic signaling, DNA repair, AR, TP53/RB1, PTEN, and WNT pathways.	enzalutamide	147-159	tumor protein p53	Homo sapiens	278-282	
31587305-4	2020	Importantly, knockdown of SOX2 in the context of RB1 and TP53 depletion restored sensitivity to enzalutamide and reduced the expression of neuroendocrine markers.	enzalutamide	96-108	tumor protein p53	Homo sapiens	57-61	
31046065-0	2019	Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.	enzalutamide	61-73	tumor protein p53	Homo sapiens	77-81	
31822380-8	2020	However, TP53 GOF mutations had a positive association with prior abiraterone/enzalutamide therapy (P = .047).	enzalutamide	78-90	tumor protein p53	Homo sapiens	9-13	
31297844-12	2019	Our data, therefore, suggest that enzalutamide"s high efficacy is at least partially independent of AR and p53 protein expression, which are frequently lost in advanced PC.	enzalutamide	34-46	tumor protein p53	Homo sapiens	107-110	
30209161-0	2019	TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.	enzalutamide	78-90	tumor protein p53	Homo sapiens	0-4	
29302046-0	2018	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.	enzalutamide	80-92	tumor protein p53	Homo sapiens	0-3